Ann: Expanded collaboration with Siemens Healthineers to US, page-102

I'd like to see management come out and tell us how they are going to run the phase 2 trial differently. I don't believe that COVID is to blame for the extended trial. We had 4 trial sites up and running across multiple states - each recruited about 3-4 patients in 2.5 years! The available patient population was more than enough to recruit 15 patients. Patient incentives is a good point. However main issue was the trial design - it really was cumbersome for a patient to go through all of the additional scans and tests over a 4 week period in addition to what they were experiencing and going through following a new cancer diagnosis. For this reason I don't buy that moving to the US will magically fix things when in reality the phase 2 will need many more patients than the phase 1. The 200million mc was based on pure froth at the time - you could throw a dart at a dartboard and pick a stock that was going to go up. Now companies have to earn valuations like that.